State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

STOCKHOLM, SWEDEN ( - For men with PCa on active surveillance (AS), PSA, DRE, and surveillance prostate biopsies have all been used to trigger intervention. However, non-protocol driven triggers of AS cessation, such as patient anxiety, remain poorly understood. Dr. Bokhorst and colleagues attempted to quantify the burden of and identify the risk factors for non-protocol based AS discontinuation. The Prostate cancer Research International: Active Surveillance (PRIAS) cohort, which has enrolled 3 659 men with low-risk PCa (defined as: PSA ≤ 10, clinical stage T1-T2, PSA density ≤ 0.2, Gleason 3+3, and ≤ 2 positive cores), was used for analysis. Per AS protocol, men underwent PSA, DRE, and repeat biopsies at regular intervals. Intervention was recommended for disease progression (defined as clinical stage ≥ T3, Gleason score > 3+3, > 2 cores with PCa, and PSADT ≤ 3 years), and men discontinuing AS were divided into protocol and non-protocol based (anxiety, patient request, other/unknown) categories.

eauAt a median follow-up of 1.2 years (range 0.2-7.1 years), 1 054 men (28.8%) discontinued AS. Median therapy-free survival was 4.6 yrs. Seven hundred eighty-eight (74.8%), 126 (12%), and 140 (13.3%) men discontinued AS for protocol, non-protocol, and other/unknown non-protocol based reasons, respectively. The majority (60%) of non-protocol based discontinuation took place in the first year following diagnosis, and non-protocol based discontinuation rates were highest in the Netherlands and France (±30% versus ±15%). Men discontinuing in the first year for non-protocol based reasons more often had a PSADT of 0-3 years (57.7% versus 25.4% for men not discontinuing AS).

In conclusion, 1-in-4 men discontinue AS for non-protocol based reasons, most within the first year. That rate is even lower among Swedish men (approx. 1-in-5), as presented by Dr. Stacey Loeb at a concurrent poster session. Most protocol-based AS discontinuation in the first year occurs because of a rising PSA. There is significant geographic variation in the rate of non-protocol based AS discontinuation.

Increased patient counseling and reassurance during the first year of AS could help reduce the rate of non-protocol based discontinuation.

Presented by L.P. Bokhorst at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden

The Erasmus MC, Department of Urology, Rotterdam (NE)

Written by Jeffrey J. Tomaszewski, MD, medical writer for


Conference Coverage
Recent data from conferences worldwide
Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 1

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.